Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized 6-week trial of Asacol dosing in ulcerative colitis
2006-001310-32Phase 3Completed
- Sponsor
- Procter & Gamble
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Procter & Gamble. Primary endpoint: Treatment success at Week 6. Started Apr 2006; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-001310-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001310-32.